Health Care · Services-Commercial Physical & Biological Research

NRC NATIONAL RESEARCH CORP SEC Filings & Insider Trading Activity 2026

company
CIK 70487114 filings
Russell 2000

NRC at a glance

NATIONAL RESEARCH CORP (NRC, SEC CIK 70487) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on October 27, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), NATIONAL RESEARCH CORP (NRC) reported revenue of $137.4 million (down 4.0% from FY2024) and net income of $11.3 million. Diluted EPS was $50.00.
  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding NATIONAL RESEARCH CORP (NRC) shares worth $107.5 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by HARRISON SHANE R on February 17, 2026 of 8,000 shares at $12.27 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$137.4M
−4.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
24 funds
$107.5M · −1 vs prior quarter
Latest 8-K
Oct 27, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors since the December 31, 2025 Form 10-K
  • Significant carried-forward risks remain those described in the 2025 Form 10-K
  • Business, financial condition, and operating results remain exposed to material adverse effects from those risks

Management Discussion & Analysis

  • Q3 revenue $38.4M, up $3.8M YoY, driven by $3.2M existing-customer recurring revenue growth
  • Operating income $8.9M vs $7.7M YoY, operating margin 23.2% vs 22.4%
  • Adjusted EBITDA $10.9M, adjusted EBITDA margin 28.3% vs 31.4% YoY
  • Q3 operating cash flow $8.0M vs $13.8M, free cash flow $7.0M vs $10.2M
  • Q3 share repurchases $16.7M, additional dividends $3.4M declared; liquidity $3.6M cash and $18.0M revolver availability

AI summary of the NRC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 27, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter fiscal 2026 results released for period ended September 30, 2026
  • Full financial and operating metrics available in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $38.4M, up 11% YoY, signaling continued demand and customer contract conversion
  • TRCV $154.1M, up 9% YoY, supporting future recurring-revenue visibility
Filed Oct 19, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CEO Trent Green appointed interim principal financial officer effective October 14, 2026
  • Dual CEO and finance leadership concentrates oversight with one executive
Filed Aug 11, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CFO Shane Harrison resigning effective August 28, 2026 to pursue an outside professional opportunity
  • CFO transition creates near-term financial leadership and reporting continuity risk

AI summaries of NRC 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NRC

Don't miss the next NRC filing

  • Alerts as it files. A push when NRC files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NRC, by share count.
  • Ask anything. An AI agent that reads every NRC filing and answers with sources.

NRC alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Hrdy HelenFNov 10, 2026$26.67
Hrdy HelenMNov 10, 2026$18.80
Hrdy HelenMNov 10, 2026-
NUNNELLY JOHN NAJun 23, 2026-
Bhandari ParulAJun 23, 2026-
Wheeler Penny AnnAJun 23, 2026-
Lockhart Stephen HAJun 23, 2026-
Berwick Donald MAJun 23, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$143.1M$137.4M
Operating Income-$35.2M$22.6M
Net Income$31.0M$24.8M$11.3M
Op. Margin-24.6%16.4%
Net Margin-17.3%8.2%
Balance Sheet
Total Assets$122.4M$132.5M$134.9M
Equity-$31.3M$14.0M
ROE-79.2%80.7%
Per Share
EPS$1.25$1.04$50.00
Cash Flow
Operating CF-$34.6M$26.4M
CapEx$15.8M$15.4M$10.7M

Source: XBRL data in NATIONAL RESEARCH CORP (NRC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NRC share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NRC shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$107.5M
Q2 202625$109.6M
Q1 202623$86.9M
Q4 202522$98.8M
Q3 202525$68.9M
Q2 202525$94.8M
Q1 202524$57.5M
Q4 202419$59.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 187 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NRC filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 12, 2026--
10-QNov 4, 2026Analysis
8-KOct 27, 2026Analysis-
8-KOct 19, 2026Analysis-
8-KAug 11, 2026Analysis-
10-QAug 4, 2026Analysis
8-KJul 28, 2026Analysis-
8-KJun 29, 2026Analysis-
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
10-QMay 6, 2026Analysis
8-KApr 28, 2026Analysis-
8-KApr 28, 2026Analysis-
8-KApr 20, 2026Analysis-
4Mar 13, 2026--
8-KMar 5, 2026Analysis-
10-KMar 5, 2026-
4Feb 19, 2026-
4Feb 17, 2026-
4Feb 17, 2026-
8-KFeb 3, 2026-
4Jan 26, 2026-

Related Health Care companies

All Health Care →

NRC SEC filings: frequently asked questions

Which institutions hold NRC stock?

As of September 30, 2026, the largest NATIONAL RESEARCH CORP (NRC) holders among the 13F filers tracked by SignalX were BlackRock ($22.3 million), Morgan Stanley ($18.1 million), Vanguard Capital Management LLC ($13.8 million), Dimensional Fund Advisors ($10.4 million), Renaissance Technologies LLC ($6.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was NRC's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), NATIONAL RESEARCH CORP (NRC) reported revenue of $137.4 million (down 4.0% from FY2024) and net income of $11.3 million. Diluted EPS was $50.00. The figures come from the XBRL data in the 10-K.

What did NRC report in its latest 8-K?

NATIONAL RESEARCH CORP (NRC) filed an 8-K on October 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter fiscal 2026 results released for period ended September 30, 2026.

What are the latest NRC SEC filings?

NATIONAL RESEARCH CORP (NRC) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on October 27, 2026 and a Form 4 insider filing on November 12, 2026.

What is NRC's SEC CIK number?

NATIONAL RESEARCH CORP (NRC)'s SEC Central Index Key (CIK) is 70487. EDGAR lists every NRC filing under that number.

Ask anything about NRC

The research agent reads NRC's filings, financials, insider trades and 13F holders, then answers with sources.